I don’t think proteomics will win over genomics," Sanghera said. "They go hand-in-glove. We’ve been overly focused [on genomics], and now we’re going to see an emergence of proteomics. And when the ...

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today announced that the European ...

European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria plus Rekambys for HIV treatment in adolescents: London, UK Saturday, February 1, 2025, 11:00 Hrs ...

According to a study published in Advanced Functional Materials on November 24th, 2024, a group of researchers led by ...

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study ...

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...

Fans are encouraged to arrive early ahead of kick-off in this weekend's Soweto derby between Orlando Pirates and Kaizer Chiefs.

Another year, another soul-crushing playoff defeat for the Buffalo Bills at the hands of the Kansas City Chiefs. Bills general manager Brandon Beane held his end-of-season press conference and made ...

London: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as ...

A.forall announced through its U.S. subsidiary, Milla Pharmaceuticals Inc., that it has received Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration (FDA) for a ...

ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and olde ...